Biolife Sciences (Biolife Sciences) Change In Receivables : $0.06 Mil (TTM As of May. 2008)

View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Change In Receivables?

Biolife Sciences's change in receivables for the quarter that ended in May. 2008 was $0.03 Mil. It means Biolife Sciences's Accounts Receivable declined by $0.03 Mil from Feb. 2008 to May. 2008 .

Biolife Sciences's change in receivables for the fiscal year that ended in Nov. 2007 was $0.10 Mil. It means Biolife Sciences's Accounts Receivable declined by $0.10 Mil from Nov. 2006 to Nov. 2007 .

Biolife Sciences's Accounts Receivable for the quarter that ended in May. 2008 was $0.14 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biolife Sciences's Days Sales Outstanding for the three months ended in May. 2008 was 7.26.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biolife Sciences's liquidation value for the three months ended in May. 2008 was $-3.31 Mil.

Biolife Sciences Change In Receivables Historical Data

The historical data trend for Biolife Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Change In Receivables Chart

Biolife Sciences Annual Data

Trend

Nov04

Nov05

Nov06

Nov07

Change In Receivables

-0.02

-0.56

0.10

Biolife Sciences Quarterly Data
	Nov04	Feb05	May05	Aug05	Nov05	Feb06	May06	Aug06	Nov06	Feb07	May07	Aug07	Nov07	Feb08	May08
Change In Receivables	Get a 7-Day Free Trial										-0.01	0.10	-0.07	-0.01	0.03

Biolife Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in May. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.

Biolife Sciences (OTCPK:BLFE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biolife Sciences's Days Sales Outstanding for the quarter that ended in May. 2008 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.143	/	1.798	*	91
=	7.26

2. In Ben Graham's calculation of liquidation value, Biolife Sciences's accounts receivable are only considered to be worth 75% of book value:

Biolife Sciences's liquidation value for the quarter that ended in May. 2008 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.04	-	3.46	+	0.75 * 0.143	+	0.5 * 0
=	-3.31

Biolife Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolife Sciences (Biolife Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052

Website

https://www.biolifesciences.com

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Executives

Arthur Viola

director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired • 09-15-2020